申聯生物(688098.SH):獲批新獸藥註冊
格隆匯7月18日丨申聯生物(688098.SH)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》規定,經中華人民共和國農業農村部審查,批准公司及其他單位聯合研製的禽腺病毒(Ⅰ羣,4型)滅活疫苗(DN株)為新獸藥,並核發《新獸藥註冊證書》。該產品系公司與貴州福斯特生物科技有限公司等單位聯合研發申報的產品,用於預防禽腺病毒(Ⅰ羣,4型)引起的禽腺病毒病。禽腺病毒病,是目前危害世界養禽業的重要疫病之一,給養禽業造成了巨大經濟損失。禽腺病毒Ⅰ羣4型是禽腺病毒I羣中的重要致病血清型,主要感染肉雞和蛋雞,引發心包積液-肝炎綜合徵等,具有高致病性和快速傳播特點。禽腺病毒(Ⅰ羣,4型)滅活疫苗(DN株)採用全病毒培養工藝,能完整保留病毒表面蛋白的天然構象,確保誘導的免疫應答更接近自然狀態,為禽類提供更全面的免疫保護。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.